Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): A randomised, open-label trial

The Lancet

Volumn 385, Issue 9986, 2015, Pages 2502-2509

  Hézode, Christophe ^a   Asselah, Tarik ^b   Reddy, K Rajender ^c   Hassanein, Tarek ^d   Berenguer, Marina ^e   Fleischer Stepniewska, Katarzyna ^f   Marcellin, Patrick ^b   Hall, Coleen ^g   Schnell, Gretja ^g   Pilot Matias, Tami ^g   Mobashery, Niloufar ^g   Redman, Rebecca ^g   Vilchez, Regis A ^g   Pol, Stanislas ^h  

^a HENRI MONDOR HOSPITAL   (France)

^b BEAUJON HOSPITAL   (France)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Southern California Liver Centers and Southern California Research Center   (United States)

^e UNIVERSITY OF VALENCIA   (Spain)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g ABBVIE INC   (United States)

^h Université Paris Descartes ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; INTERLEUKIN 28B; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; VIRUS RNA; ABT-267; ABT-450; ALANINE AMINOTRANSFERASE; ANILIDE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ANXIETY DISORDER; ARTICLE; ASTHENIA; BEHAVIOR DISORDER; CHRONIC HEPATITIS C; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; FRANCE; HEADACHE; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HUNGARY; HYPERBILIRUBINEMIA; INSOMNIA; ITALY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POLAND; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; ROMANIA; SPAIN; TREATMENT RESPONSE; TURKEY (REPUBLIC); UNITED STATES; ADOLESCENT; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANILIDES; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; CARBAMATES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; RIBAVIRIN; RITONAVIR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84931569160     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60159-3     Document Type: Article

References (32)

1. World Health Organization Hepatitis C. WHO fact sheet 164 http://www.who.int/mediacentre/factsheets/fs164/en/ 2014 (accessed March 20, 2015).
2. AJ Freeman, GJ Dore, MG Law et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection Hepatology 34 2001 809 816
3. M Abdel-Hamid, M El-Daly, V Molnegren et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma J Gen Virol 88 2007 1526 1531
4. DB Smith, J Bukh, C Kuiken et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource Hepatology 59 2014 318 327
5. E Gower, CC Estes, Hindman, K Razavi-Shearer, H Razavi Global epidemiology and genotype distribution of the hepatitis C virus infection J Hepatol 61 2014 S45 S47
6. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Recommendations for testing, managing, and treating hepatitis C http://www.HCVguidelines.org 2014 (accessed March 20, 2015).
7. J Brok, LL Gluud, C Gluud Ribavirin monotherapy for chronic hepatitis C Cochrane Database Syst Rev 4 2009 CD005527.
8. European Association for the Study of the Liver EASL recommendations on treatment of hepatitis C http://www.easl.eu/assets/application/files/easl-recommendations-hcv-2014-full.pdf 2014 (accessed March 20, 2015).
9. R Schinazi, P Halfon, P Marcellin, T Asselah HCV direct-acting antiviral agents: the best interferon-free combinations Liver Int 34 2014 69 78
10. N Afdhal, S Zeuzem, P Kwo et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
11. P Andreone, MG Colombo, JV Enejosa et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection Gastroenterology 147 2014 359 365
12. P Ferenci, D Bernstein, J Lalezari et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV N Engl J Med 370 2014 1983 1992
13. KV Kowdley, SC Gordon, KR Reddy et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 2014 1879 1888
14. S Zeuzem, IM Jacobson, T Baykal et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1604 1614
15. Y Benhamou, J Moussalli, V Ratziu et al. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial J Infect Dis 208 2013 1000 1007
16. DA DeGoey, JT Randolph, D Liu et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A J Med Chem 57 2014 2047 2057
17. T Pilot-Matias, R Tripathi, D Cohen et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450 Antimicrob Agents Chemother 59 2015 988 997
18. P Krishnan, J Beyer, N Mistry et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of HCV NS5A Antimicrob Agents Chemother 59 2014 979 987
19. RM Menon, CE Klein, AA Lawal et al. Pharmacokinetics and tolerability of the HCV protease inhibitor ABT-450 following single ascending doses in healthy adult volunteers with and without ritonavir (HEP DART 2009 abstract 57) Glob Antiviral J 5 2009 53
20. JJ Feld, KV Kowdley, E Coakley et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1594 1603
21. F Poordad, C Hezode, R Trinh et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982
22. FA Di Lello, K Neukam, M Parra-Sanchez et al. Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves J Med Virol 85 2013 1734 1740
23. D Koletzki, S Dumont, H Vermeiren, B Fevery, P De Smet, LJ Stuyver Development and evaluation of an automated hepatitis C virus NS5B sequence-based subtyping assay Clin Chem Lab Med 48 2010 1095 1102
24. SM Kamal Improving outcome in patients with hepatitis C virus genotype 4 Am J Gastroenterol 102 2007 2582 2588
25. G Esmat, M El Raziky, M El Kassas, M Hassany, ME Gamil The future for the treatment of genotype 4 chronic hepatitis C Liver Int 32 2012 146 150
26. E Lawitz, A Mangia, D Wyles et al. Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
27. JP Bronowicki, V Ratziu, A Gadano et al. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C J Hepatol 61 2014 1220 1227
28. C Hezode, GM Hirschfield, W Ghesquiere et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study Gut 2014 10.1136/gutjnl-2014-307498 published online July 30.
29. GE Esmat, G Shiha, RF Omar et al. Sofosbuvir plus ribavirin in the treatment of Egyptian patients with chronic genotype 4 HCV infection Hepatology 60 2014 662A 663A
30. R Kapoor, A Kohli, S Sidharthan et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial Hepatology 60 2014 Abs 321.
31. T Asselah, S De Muynck, P Broet et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C J Hepatol 56 2012 527 532
32. S Zeuzem, V Soriano, T Asselah et al. Faldaprevir and deleobuvir for HCV genotype 1 infection N Engl J Med 369 2013 630 639